Introduction {#s1}
============

Vitiligo is characterized by the loss of functional skin and mucosal melanocytes, the estimated prevalence is 0.5--2% ([@B1], [@B2]). Currently, the exact pathogenesis of vitiligo remains obscure. The most accredited hypothesis is the autoimmune theory, being sustained by several epidemiological, clinical, and experimental findings ([@B3]--[@B5]). These studies indicate that melanocyte defects drive vitiligo pathogenesis by triggering an autoimmune response that leads to melanocyte destruction in susceptible individuals. Patients with vitiligo are more likely to suffer from autoimmune conditions than the general population ([@B6]). Several studies have suggested vitiligo is associated with a variety of other autoimmune diseases, including thyroid conditions, alopecia areata, type 1 diabetes mellitus, pernicious anemia, and rheumatoid arthritis. Among these, thyroid disorders are common conditions in vitiligo patients, and a recent study showed one of the most frequently observed autoimmune diseases in autoimmune thyroiditis patients was vitiligo ([@B7], [@B8]). A genetic co-localization between vitiligo and thyroid autoantibodies has also been proposed ([@B9]). The British guidelines suggested to check the thyroid function for adult patients with vitiligo, the Dutch guidelines recommend that when patients with vitiligo have clinical symptoms of thyroid disease, thyroid function should be tested ([@B10], [@B11]) Herein, we conducted a systematic review and meta-analysis to explore the prevalence of various kind of thyroid disorders in patients with vitiligo.

Methods {#s2}
=======

Electronic Search
-----------------

The PubMed, Cochrane Library, EMBASE, CNKI (China National Knowledge Infrastructure), Chongqing VIP database, and Wanfang database were systematically searched with different combinations of key words to identify studies on thyroid disorders in vitiligo. The studies published in the period from inception to August 2, 2018 were identified. The search keywords were \[vitiligo\] AND \[thyroid\] with \["prevalence" OR "incidence" OR "epidemiology"\]. A manual search was performed by checking the reference lists of key studies and review articles before they were excluded to identify additional studies.

Inclusion and Exclusion Criteria
--------------------------------

Studies were included if they met the following eligibility criteria: (1) provided sufficient information to estimate the prevalence of thyroid disorders in patients with vitiligo; (2) published in either English or Chinese language; (3) had the exact diagnosis of thyroid disorders. The exclusion criteria were duplicate data, irrelevant to vitiligo, review, data mistake, not providing sufficient information. Obscure terms, such as thyroid disfunction, thyroid disease, and autoimmune thyroid disease, or no categorical diagnoses were excluded.

Data Extraction
---------------

Data was extracted from each article using a standardized data-abstraction form, designed in advance. All the potentially relevant papers were reviewed independently by two investigators. Disagreements were resolved through discussion. The following characteristics were extracted: first authors\' name, year of publication, country area, number of vitiligo patients, number of different type, or stage of vitiligo patients who have thyroid disorders, number of male and female patients, number, or prevalence of thyroid disorders in vitiligo patients, duration of vitiligo, survey age, adults or children.

Data Analysis
-------------

All statistical analyses were carried out in Stata software (v15.0; Stata Corp, College Station, TX, USA) and a *p* \< 0.05 was deemed statistically significant. To explore the prevalence of each thyroid disorder in vitiligo patients, the pooled prevalence and its 95%CI were calculated. Random-effects models were used, if the *p* \< 0.05, *I*^2^ \> 50%, otherwise, a fixed-effect model was selected (*p* \> 0.05, *I*^2^ \< 50%). Subgroup analyses based on areas, gender, age, vitiligo type, and vitiligo stage were done to assess sources of heterogeneity. Sensitivity analysis was performed by eliminating individual studies one by one. The effect of publication bias was assessed by Egger\'s test.

Results {#s3}
=======

Study Flow and Characteristics
------------------------------

A total of 3,643 articles were screened. Of these, 3,566 were excluded for the following reasons: not relevant to our topic, duplication, review, not English or Chinese, not providing sufficient information or data mistake, no categorical diagnoses (for example, thyroid goiter). Finally, 77 studies met the inclusion criteria, and were included in this systematic review and meta-analysis ([@B12]--[@B88]). Of these studies, 2 studies were reported by one author in the same year, sharing the common basic data, but respectively provided some different data. The detailed selection process was shown in Figure [1](#F1){ref-type="fig"}.

![Flow diagram of the study selection process.](fendo-09-00803-g0001){#F1}

The characteristics of included studies were described in Table [1](#T1){ref-type="table"}. The publication years were from 1968 to 2018. The countries covered France, Netherland, Greece, Serbia, Bulgaria, FRG (the Federal Republic of Germany), Italy, Spain, Austria, England, Denmark, USA, Washington, Colorado, California, Canada, Brazil, China, India, Turkey, Korea, Japan, Iran, Thailand, and Nigeria. The areas covered Europe (France, Netherland, Greece, Serbia, Bulgaria, FRG, Italy, Spain, Austria, England, Denmark), North America (USA, Washington, Colorado, California, Canada), South America (Brazil), Asia (China, India, Turkey, Korea, Japan, Iran, Thailand), and Africa (Nigeria). The number of patients with thyroid disorders ranged from 35 to 73,336.

###### 

Characteristics of studies on the prevalence of thyroid disorders in patients with vitiligo.

  **References**                       **Country**   **Vitiligo (*n*)**   **Male/Female**   **Duation (years)**       **Survey age (years)**   **Adult/Children**   **Prevalence**                                   
  ------------------------------------ ------------- -------------------- ----------------- ------------------------- ------------------------ -------------------- ---------------- ------- ------- ------- ------- -------
  Wan and Chen ([@B12])                China         324                  161/163           ---                       ---                      Adult + children     ---              3.09    ---     ---     0.93    ---
  Vachiramon et al. ([@B13])           Thailand      197                  ---               ---                       ---                      ---                  ---              ---     ---     ---     6.60    4.06
  Topal et al. ([@B18])                Turkey        100                  51/49             4.9 ± 6.7 (1M−39)         34.9 ± 16.8 (3--78)      Adult + children     ---              ---     ---     5.00    ---     ---
  Yazdanpanah et al. ([@B19])          Iran          72                   40/32             ---                       27.04 ± 1.22             ---                  ---              ---     27.78   ---     ---     ---
  Kartal et al. ([@B17])               Turkey        155                  80/75             ---                       ---                      Children             0.65             ---     0.65    ---     ---     1.29
  Bae et al. ([@B15])                  Korea         73,336               32,519/40,817     ---                       ---                      Adult + children     ---              ---     ---     ---     0.86    0.75
  Wang et al. ([@B16])                 China         67                   30/37             ---                       29.15 ± 13.74 (5--70)    Adult + children     ---              5.97    ---     10.45   ---     ---
  Wang and Wang ([@B14])               China         100                  31/69             ---                       21.6 ± 5.8 (18--62)      Adult                ---              17.00   ---     ---     ---     ---
  Gill et al. ([@B24])                 USA           1,098                508/590           ---                       4.8--99.8                Adult + children     ---              0.91    ---     8.65    1.09    1.28
  Díaz--Angulo et al. ([@B79])         Spain         71                   34/37             ---                       ---                      Adult + children     1.41             9.86    8.45    1.41    ---     ---
  Chen and Chen ([@B20])               China         352                  177/175           55D−4.5                   5--56                    Adult + children     ---              0.57    ---     2.27    ---     ---
  Wang et al. ([@B21])                 China         60                   18/42             ---                       22 ± 6.4 (18--58)        Adult                ---              16.67   ---     ---     ---     ---
  Cheng et al. ([@B23])                Chia          145                  88/57             ---                       10.73 ± 3.73 (2--17)     Children             ---              ---     4.14    2.76    ---     ---
  Dash et al. ([@B25])                 India         100                  41/59             4.64 ± 6.05               29.49 ± 15 (2--62)       Adult + children     ---              3.00    ---     13.00   ---     ---
  Ma and Li ([@B22])                   China         978                  540/438           ---                       37.2 ± 10.7 (5--85)      Adult + children     ---              1.33    ---     1.64    ---     ---
  Qin ([@B26])                         China         413                  253/160           ---                       ---                      Adult + children     ---              0.97    ---     ---     ---     ---
  Ingordo et al. ([@B33])              Italy         154                  52/123            ---                       ---                      Adult + children     1.30             3.25    1.95    19.48   ---     ---
  Colucci et al. ([@B31])              Italy         79                   26/53             11.67 ± 11.85             38.45 ± 16.0 (18--73)    Adult                2.53             5.06    2.53    3.80    ---     ---
  XU and XU ([@B32])                   China         1,386                690/696           ---                       ---                      Adult + children     ---              5.34    ---     2.60    ---     ---
  Wang et al. ([@B30])                 China         215                  98/117            1W−60                     35.14 ± 16.65            Adult                ---              3.26    ---     0.93    ---     1.40
  Gopal et al. ([@B28])                India         150                  83/67             9--63                     3.4 ± 1.77 (3W−26)       Adult + childre      ---              0.00    ---     20.00   ---     ---
  Zhang et al. ([@B29])                China         60                   26/34             12.3 ± 8.2                35 ± 12                  Adult                ---              ---     8.33    ---     ---     ---
  Yu and Miao ([@B27])                 China         606                  309/297           2.96 ± 5.22               23.50 ± 14.79 (2M−74)    Adult + children     ---              2.48    ---     1.32    ---     ---
  Afsar and Isleten ([@B36])           Turkey        79                   29/50             ---                       8.19 ± 3.45 (2--5)       Children             ---              ---     16.46   2.53    ---     ---
  Nejad et al. ([@B37])                Iran          86                   33/52             6                         28.11 ± 12.5             Adult + children     ---              6.98    6.98    6.98    ---     ---
  Agarwal et al. ([@B38])              India         268                  116/152           1M−10                     ---                      Children             ---              2.24    ---     6.72    ---     ---
  Sheth et al. ([@B34])                USA           2,441                ---               ---                       ---                      ---                  ---              1.19    ---     7.66    0.98    ---
  Gey et al. ([@B39])                  France        626                  216/49            ---                       31 ± 18.76 (1--74)       Adult + children     1.92             2.56    8.15    8.31    ---     ---
  Kroon et al. ([@B44])                Netherlands   260                  110/150           ---                       ---                      Children             0.38             ---     5.38    1.15    ---     ---
  Yang and Wang ([@B45])               China         540                  284/256           23.37 ± 13.45 (1W−42)     ---                      Adult + children     ---              1.30    ---     0.74    ---     ---
  Kang et al. ([@B35])                 China         521                  272/249           ---                       ---                      Adult + children     ---              1.54    ---     ---     ---     ---
  Sawicki et al. ([@B43])              Canada        300                  141/159           ---                       41.5 ± 15.5 (11--82)     Adult + children     ---              0.67    ---     12.00   ---     ---
  Kumar et al. ([@B46])                India         50                   21/29             5.5 ± 4.3                 42.7 ± 17 (18--70)       Adult                ---              0.00    28.00   0.00    ---     ---
  Kroon et al. ([@B47])                Netherlands   434                  216/218           ---                       ---                      Adult                0.69             1.15    1.61    8.53    ---     ---
  Jian et al. ([@B41])                 China         10,000               5,322/4,678       46.17 ± 67.8 (10D−50)     ---                      ---                  ---              0.52    ---     0.14    ---     ---
  Cheng et al. ([@B42])                China         287                  143/144           3.0 ± 5.6 (2D−40)         21.8 ± 14.8 (2M−74)      Adult + children     ---              0.70    ---     1.05    ---     ---
  Wei et al. ([@B40])                  China         1,125                573/552           ---                       ---                      Children             ---              0.09    ---     0.18    ---     ---
  Pradhan et al. ([@B48])              India         79                   40/39             ---                       ---                      Adult + children     ---              ---     ---     1.27    ---     ---
  Nunes and Nunes ([@B50])             Brazil        85                   29/56             ---                       37.14 ± 18.64 (6--78)    Adult + children     ---              2.35    1.18    14.12   ---     ---
  Prćić et al. ([@B51])                Serbia        75                   28/47             2.6 ± 2.6 (1M−12)         10.81 ± 4.06 (6M−17.7)   Children             ---              ---     2.66    5.33    ---     14.67
  Uncu et al. ([@B53])                 Turkey        50                   26/24             2.26 ± 2.95               9.52 ± 4.54              Children             ---              0.00    10.00   0.00    ---     ---
  Narita et al. ([@B54])               Japan         133                  57/76             8.2 ± 8.6 (0--63)         49.3 ± 19.8 (3--89)      Adult + children     ---              ---     ---     ---     4.51    7.52
  Tang et al. ([@B55])                 China         1,367                630/737           1M−30                     1--79                    Adult + children     ---              0.29    ---     0.15    ---     0.07
  Poojary ([@B56])                     India         204                  100/104           ---                       6M−79                    Adult + children     ---              ---     ---     ---     0.49    ---
  Cho et al. ([@B49])                  Korea         254                  158/166           ---                       ---                      Adult + children     0.79             ---     2.76            0.79    1.57
  Ingordo et al. ([@B52])              Italy         40                   40                ---                       ---                      Adult                ---              2.50    2.50    2.50    ---     ---
  Angulo et al. ([@B57])               Spain         83                   39/44             ---                       36.35 ± 18.83            ---                  1.40             10.00   ---     ---     ---     ---
  Akay et al. ([@B59])                 Turkey        80                   30/50             1M−408M                   ---                      Adult + children     ---              2.50    ---     1.25    ---     31.25
  Mazereeuw--Hautier et al. ([@B65])   France        1,14                 53/61             ---                       8.3 ± 0.7 (0.25--15)     Children             ---              ---     ---     9.38    ---     ---
  Paravar and Lee ([@B73])             California    135                  55/80             ---                       2--81                    Adult + children     ---              2.96    ---     14.07   ---     ---
  Altaf et al. ([@B58])                India         192                  91/101            ---                       6--60                    Adult + children     ---              1.04    12.50   15.10   ---     ---
  Zhou and Fu ([@B61])                 China         1,049                462/587           1M−40                     18--72                   Adult                ---              1.81    ---     0.57    ---     ---
  Yang et al. ([@B63])                 China         363                  198/165           1M−11                     3--13                    Children             ---              0.83    ---     4.41    ---     ---
  Tanioka et al. ([@B64])              Japan         144                  49/49             ---                       ---                      ---                  ---              ---     ---     ---     1.39    3.47
  Liu et al. ([@B60])                  China         1,097                485/612           ---                       28.8 ± 17.0              Adult + children     ---              0.82    ---     ---     ---     ---
  Zhang et al. ([@B67])                China         6,199                3,276/2,923       1.5 ± 4.5 (0--961M)       24.5 ± 14.6 (1--91)      Adult + children     ---              1.16    ---     1.00    ---     ---
  Birlea et al. ([@B66])               Colorado      51                   18/33             ---                       49.5 ± 22.8 (2--83)      Adult + children     ---              ---     ---     ---     0.00    15.69
  Yang and Yang ([@B68])               China         87                   43/44             10D−27                    32.9 ± 14.3 (4--72)      Adult + children     ---              ---     1.15    ---     1.15    14.94
  Sedighe and Gholamhossein ([@B69])   Iran          109                  38/79             ---                       34.41 ± 13 (8--65)       Adult + children     ---              ---     12.84   14.68   0.92    ---
  Gopal et al. ([@B74])                India         150                  81/69             15D−31                    10--55                   Adult + children     ---              ---     ---     12.00   ---     ---
  Yang et al. ([@B70])                 China         38                   13/25             1.5--10                   13--56                   Adult + children     ---              ---             2.63    13.16   7.89
  Wu et al. ([@B71])                   China         3,143                ---               ---                       ---                      Adult + children     ---              0.89    ---     0.76    ---     ---
  Fang and Tian ([@B72])               China         562                  276/286           2D−43                     40D−69                   Adult + children     ---              2.14    ---     0.36    ---     ---
  Daneshpazhooh et al. ([@B75])        Iran          94                   48/46             0--40                     28.67 ± 15.42            Adult + children     ---              ---     1.06    ---     1.06    ---
  Laberge et al. ([@B77])              USA           133                  ---               ---                       ---                      ---                  ---              6.02    ---     16.54   ---     ---
  Kakourou et al. ([@B76])             Greece        54                   23/31             3.7 ± 3.6 (0.16--15.75)   11.4 ± 4.89              Children             ---              ---     20.47   3.70    ---     7.41
  Kurtev and Dourmishev ([@B78])       Bulgaria      61                   26/35             0.08--11                  1.16--16.16              Children             ---              5.17    8.62    ---     ---     ---
  Iacovelli ([@B81])                   Italy         121                  40/81             1M−11                     3--13                    Children             ---              0.83    ---     4.96    ---     ---
  Onunu and Kubeyinje ([@B80])         Nigeria       351                  153/198           ---                       9M−80                    Adult + children     ---              0.57    ---             ---     ---
  Zettinig et al. ([@B82])             Austria       106                  42/64             ---                       39 ± 18 (6--80)          Adult + children     1.89             ---     3.77    11.32   0.00    3.77
  Martis et al. ([@B83])               India         100                  45/55             ---                       ---                      ---                  ---              ---     ---     2.00    ---     ---
  Hegedus et al. ([@B88])              Denmark       35                   ---               ---                       ---                      ---                  ---              17.14   ---     5.71    ---     ---
  Schallreuter et al. ([@B84])         FRG           321                  114/207           2M−65                     1--85                    Adult + children     ---              3.74    ---     3.43    0.62    0.31
  Betterle et al. ([@B85])             Italy         373                  138/235           ---                       7--80                    Adult + children     ---              ---     ---     ---     4.29    1.88
  Grimes et al. ([@B86])               Washington    70                   24/46             ---                       3--73                    Adult + children     ---              5.71    ---     4.29    ---     ---
  Cunliffe et al. ([@B87])             England       56                   14/42             ---                       38 ± 18.6                ---                  ---              5.36    ---     ---     ---     12.50

*SHyper, subclinical hyperthyroidism; OHyper, overt hyperthyroidism; SHypo, subclinical hypothyroidism; OHypo, overt hypothyroidism; GD, Graves disease; HT, Hashimoto thyroiditis; M, month; W, week; D, day*.

Six thyroid disorders were described in the study. They were subclinical hyperthyroidism, overt hyperthyroidism, subclinical hypothyroidism, overt hypothyroidism, Graves disease, and Hashimoto thyroiditis. The number of studies on the 6 above mentioned thyroid disorders in vitiligo patients were 54 on overt hypothyroidism, 50 on overt hyperthyroidism, 25 on subclinical hypothyroidism, 19 on Hashimoto thyroiditis, 16 on Graves disease, and 10 on subclinical hyperthyroidism (Table [2](#T2){ref-type="table"}). The data of vitiligo patients who accompanied with one of the following 5 thyroid disorders including thyroid cancer, toxic nodular goiter, thyroid adenoma or asymptomatic atrophic thyroiditis, was not extracted as only 1 study was reported in each disorder.

###### 

The pooled prevalence and subgroup analysis of thyroid disorders in vitiligo patients.

                                         **Stratified factors**   **No. of studies**   **Prevalence rate**   **Lower limit**   **Upper limit**   **Heterogeneity *I*^**2**^ (%)**   ***P* from test of heterogeneity**   **Model**
  ----------------------------- -------- ------------------------ -------------------- --------------------- ----------------- ----------------- ---------------------------------- ------------------------------------ -----------
  Subclinical hyperthyroidism            Overall                  10                   0.01                  0.00              0.01              0.0%                               0.568                                Fixed
                                Area     Europe                   8                    0.01                  0.00              0.01              6.2%                               0.382                                Fixed
                                         Asia                     2                    0.01                  −0.00             0.02              0.0%                               0.869                                Fixed
                                Gender   Male                     2                    0.01                  −0.00             0.02              100%                               ---                                  ---
                                         Female                   2                    0.01                  −0.00             0.01              0.0%                               0.795                                Fixed
                                Age      Children                 2                    0.00                  −0.00             0.01              0.0%                               0.719                                Fixed
                                         Adults                   2                    0.01                  0.00              0.02              3.1%                               0.310                                Fixed
                                Type     SV                       2                    0.00                  ---               ---               ---                                ---                                  ---
                                         NSV                      6                    0.01                  0.00              0.01              0.0%                               0.825                                Fixed
                                Stage    Active                   1                    0.02                  −0.02             0.07              ---                                ---                                  ---
  Overt hyperthyroidism                  Overall                  50                   0.02                  0.01              0.02              83.9%                              0.000                                Random
                                Area     Europe                   11                   0.03                  0.02              0.05              65.8%                              0.001                                Random
                                         North America            7                    0.01                  0.01              0.01              49.3%                              0.066                                Fixed
                                         South America            1                    0.02                  −0.01             0.06              ---                                ---                                  ---
                                         Asia                     30                   0.01                  0.01              0.02              87.7%                              0.000                                Random
                                         Africa                   1                    0.01                  −0.00             0.01              ---                                ---                                  ---
                                Gender   Male                     9                    0.01                  0.00              0.03              81.6%                              0.000                                Random
                                         Female                   8                    0.02                  0.01              0.04              81.9%                              0.000                                Random
                                Age      Children                 9                    0.01                  0.00              0.02              0.702                              0.001                                Random
                                         Adults                   11                   0.05                  0.03              0.07              0.864                              0.000                                Random
                                Type     SV                       3                    0.00                  −0.00             0.01              42.3%                              0.188                                Fixed
                                         NSV                      6                    0.06                  0.02              0.09              95%                                0.000                                Random
                                         Generalized              2                    0.04                  0.02              0.06              34.7%                              0.216                                Fixed
                                         Acrofacial               1                    0.00                  ---               ---               ---                                ---                                  ---
                                Stage    Active                   2                    0.05                  −0.02             0.11              ---                                ---                                  ---
                                         Stable                   1                    0.00                  ---               ---               ---                                ---                                  ---
  Subclinical hypothyroidism             Overall                  25                   0.06                  0.04              0.07              83.9%                              0.000                                Random
                                Area     Europe                   10                   0.05                  0.03              0.07              80.3%                              0.000                                Random
                                         Asia                     13                   0.08                  0.05              0.11              87.9%                              0.000                                Random
                                         North America            1                    0.03                  −0.02             0.07              ---                                ---                                  ---
                                         South America            1                    0.01                  −0.01             0.03              ---                                ---                                  ---
                                Gender   Male                     4                    0.02                  0.01              0.03              0.0%                               0.521                                Fixed
                                         Female                   3                    0.03                  0.01              0.04              73.6%                              0.051                                Fixed
                                Age      Children                 8                    0.07                  0.03              0.11              85.2%                              0.000                                Random
                                         Adults                   5                    0.05                  0.01              0.10              80.4%                              0.000                                Random
                                Type     SV                       2                    0.00                  ---               ---               ---                                ---                                  ---
                                         NSV                      7                    0.04                  0.02              0.06              77.5%                              0.000                                Random
                                Stage    Active                   2                    0.25                  0.12              0.38              0.0%                               ---                                  ---
                                         Stable                   1                    0.31                  0.15              0.47              ---                                ---                                  ---
  Overt hypothyroidism                   Overall                  54                   0.03                  0.03              0.04              94.1%                              0.000                                Random
                                Area     Europe                   13                   0.06                  0.04              0.09              85.5%                              0.000                                Random
                                         North America            7                    0.09                  0.07              0.11              74.9%                              0.001                                Random
                                         South America            1                    0.14                  0.07              0.22              ---                                ---                                  ---
                                         Asia                     33                   0.01                  0.01              0.02              89.8%                              0.000                                Random
                                Gender   Male                     10                   0.02                  0.01              0.03              80.9%                              0.000                                Random
                                         Female                   9                    0.06                  0.04              0.08              91.7%                              0.000                                Random
                                Age      Children                 10                   0.04                  0.02              0.06              86.2%                              0.000                                Random
                                         Adults                   7                    0.02                  0.01              0.04              86.6%                              0.000                                Random
                                Type     SV                       3                    0.00                  −0.00             0.01              0.0%                               0.734                                Fixed
                                         NSV                      8                    0.03                  0.01              0.05              86.8%                              0.000                                Random
                                         Generalized              2                    0.10                  −0.03             0.22              92.6%                              0.000                                Random
                                         Acrofacial               1                    0.01                  −0.00             0.02              ---                                ---                                  ---
                                Stage    Active                   1                    0.02                  −0.02             0.07              ---                                ---                                  ---
  Graves disease                         Overall                  16                   0.01                  0.01              0.02              59.9%                              0.002                                Random
                                Area     Europe                   3                    0.02                  −0.01             0.06              90.4%                              0.001                                Random
                                         North America            3                    0.01                  0.00              0.02              76.1%                              0.015                                Random
                                         Asia                     10                   0.01                  0.01              0.02              56.4%                              0.014                                Random
                                Gender   Male                     4                    0.01                  0.01              0.01              58.1%                              0.122                                Fixed
                                         Female                   4                    0.01                  0.01              0.01              0.0%                               0.502                                Fixed
                                Type     SV                       2                    0.00                  ---               ---               ---                                ---                                  ---
                                         NSV                      1                    0.01                  −0.00             0.02              ---                                ---                                  ---
                                         Generalized              1                    0.02                  −0.00             0.04              ---                                ---                                  ---
                                         Vulgaris                 1                    0.01                  −0.01             0.03              ---                                ---                                  ---
  Hashimoto thyroiditis                  Overall                  19                   0.02                  0.01              0.03              92.2%                              0.000                                Random
                                Area     Europe                   6                    0.04                  0.01              0.07              83%                                0.000                                Random
                                         North America            2                    0.08                  −0.06             0.22              87.5%                              0.005                                Random
                                         Asia                     11                   0.02                  0.01              0.03              94.7%                              0.000                                Random
                                Gender   Male                     6                    0.00                  0.00              0.00              56.8%                              0.055                                Fixed
                                         Female                   6                    0.09                  0.04              0.14              85.3%                              0.000                                Random
                                Age      Children                 3                    0.07                  −0.01             0.15              83.9%                              0.002                                Random
                                         Adults                   1                    0.01                  −0.00             0.03              ---                                ---                                  ---
                                Type     SV                       4                    0.00                  ---               ---               ---                                ---                                  ---
                                         NSV                      2                    0.08                  −0.04             0.20              93.6%                              0.000                                Random
                                         Generalized              3                    0.09                  0.06              0.13              20.7%                              0.283                                Fixed
                                         Vulgaris                 1                    0.03                  0.00              0.06              ---                                ---                                  ---
                                         Acrofacial               1                    0.10                  −0.01             0.21              ---                                ---                                  ---

The diagnoses of subclinical hyperthyroidism were based on the presence of a low TSH level with both normal FT3 value and normal FT4 value and the diagnosis of overt hyperthyroidism was based on the presence of a low TSH level with both raised FT3 value and raised FT4 value ([@B52], [@B82]). The diagnosis of overt hypothyroidism required low FT3 and FT4 values no matter what the TSH level was. Subclinical hypothyroidism was diagnosed on the basis of a raised TSH level with normal T3 and T4 values. Hashimoto\'s thyroiditis was diagnosed based on the demonstration of circulating thyroid antibodies and diffuse thyroid enlargement or reduced echogenicity on thyroid ultrasonography. And the diagnosis of Graves\' disease relies on persistent hyperthyroidism together with positive thyroid antibody and/or increase vascularization on thyroid sonogram, thyroid-stimulating antibodies and diffuse hypercaptation at scintigraphy. Thyroid ophthalmopathy and/or dermopathy are characteristic features of Graves\' disease ([@B13]).

Pooled Result of the Prevalence of Thyroid Disorders in Patients With Vitiligo
------------------------------------------------------------------------------

The pooled prevalence of thyroid disorders in patients with vitiligo were showed in Table [2](#T2){ref-type="table"}. The highest prevalence of thyroid disorder accompanying vitiligo was 0.06 (95% CI: 0.04--0.07) for subclinical hypothyroidism (Figure [2A](#F2){ref-type="fig"}). The lowest prevalence was 0.01 (95% CI: 0.00--0.01) for subclinical hyperthyroidism and 0.01 (95% CI: 0.01--0.02) for Graves disease.

![The forest plot of three thyroid disorders in vitiligo patients. The highest prevalence was reported in **(A)** subclinical hypothyroidism, and a majority of investigators paid attention to **(B)** overt hypothyroidism, and **(C)** overt hyperthyroidism in vitiligo patients.](fendo-09-00803-g0002){#F2}

Subgroup Analysis of the Prevalence of Each Thyroid Disorder in Patients With Vitiligo
--------------------------------------------------------------------------------------

Potentially distorting factors, including area, vitiligo type, the stage of vitiligo, gender, and age were investigated for subgroup analysis. The areas covered Europe, North America, South America, Asia, Africa. For vitiligo type, segmental vitiligo (SV), non-segmental vitiligo (NSV), generalized vitiligo, acrofacial vitiligo, vulgaris vitiligo were classified. When stratified by the stage, it was divided into active vitiligo and stable vitiligo. For the gender, it was divided into male and female. When stratified by age, the groups were children (\<18 years) and adults (≥18 years). The results of subgroup analysis were listed in Table [2](#T2){ref-type="table"}.

Overt hypothyroidism in vitiligo patients was reported in 54 studies. The pooled prevalence was 0.03 (95% CI: 0.03--0.04) (Figure [2B](#F2){ref-type="fig"}). The prevalence in Europe, North America, South America and Asia were found to be 0.06 (95% CI: 0.04--0.09), 0.09 (95% CI: 0.07--0.11), 0.14 (95% CI: 0.07--0.22), and 0.01 (95% CI: 0.01--0.02), respectively. The highest prevalence was 0.14 (95% CI: 0.07--0.22) in South America. Male and female subgroups were 0.02 (95% CI: 0.01--0.03) and 0.06 (95% CI: 0.04--0.08), respectively. The prevalence of overt hypothyroidism in the male population was lower than in females. When stratified by age, the prevalence was higher in children 0.04 (95% CI: 0.02--0.06) than adults 0.02 (95% CI: 0.01--0.04). Pooled prevalence of segmental vitiligo, non-segmental vitiligo, generalized vitiligo, and acrofacial vitiligo were 0.00 (95% CI: −0.00 to 0.01), 0.03 (95% CI: 0.01 to 0.05), 0.10 (95% CI: −0.03 to 0.22), and 0.01 (95% CI: −0.00 to 0.02), respectively. The prevalence in generalized vitiligo was the highest.

Overt hyperthyroidism in vitiligo patients was reported in 50 studies. The pooled prevalence was 0.02 (95% CI: 0.01--0.02) (Figure [2C](#F2){ref-type="fig"}). The prevalence in Europe, North America, South America, Asia and Africa were found to be 0.03 (95% CI: 0.02 to 0.05), 0.01 (95% CI: 0.01 to 0.01), 0.02 (95% CI: −0.01 to 0.06) and 0.01 (95% CI: 0.01 to 0.02), 0.01 (95% CI: −0.00 to 0.01), respectively. The pooled prevalence in Europe was the highest. Male and female subgroups were 0.01 (95% CI: 0.00--0.03) and 0.02 (95% CI: 0.01--0.04), respectively. When stratified by age, the prevalence was higher in adults 0.05 (95% CI: 0.03--0.07) than children 0.01 (95% CI: 0.00--0.02). Pooled prevalence of segmental vitiligo, non-segmental vitiligo, generalized vitiligo, and acrofacial vitiligo were 0.00 (95% CI: −0.00 to 0.01), 0.06 (95% CI: 0.02 to 0.09), and 0.04 (95% CI: 0.02 to 0.06), respectively. The prevalence of non-segmental vitiligo was higher than the other vitiligo types.

The subgroup analysis of other 4 thyroid disorders including subclinical hyperthyroidism, subclinical hypothyroidism, Graves disease, Hashimoto thyroiditis in vitiligo patients is reported in Table [2](#T2){ref-type="table"}.

Sensitivity Analysis
--------------------

To examine the stability of the pooled prevalence of thyroid disorders in vitiligo, each study was sequentially excluded for sensitivity analysis. The results demonstrated that some individual studies significantly affected the pooled results in overt hypothyroidism and Hashimoto thyroiditis. The studies of Jian et al. ([@B41]) influenced the original results of overt hypothyroidism in vitiligo patients. After removing the study, the pooled prevalence increased by 0.54% (from 3.23 to 3.77%). After removing the study of Bae et al. ([@B15]) and Tang et al. ([@B55]) of Hashimoto thyroiditis in vitiligo patients, the pooled prevalence increased by 3.47% (from 1.94 to 5.41%).

Publication Bias
----------------

No publication bias were found in papers on overt hyperthyroidism (*t* = 1.16, *p* = 0.256) (Figure [3A](#F3){ref-type="fig"}), overt hypothyroidism (*t* = 0.95, *p* = 0.350) (Figure [3B](#F3){ref-type="fig"}), and subclinical hypothyroidism (*t* = −1.36, *p* = 0.194) (Figure [3C](#F3){ref-type="fig"}). Publication bias was found in the prevalence of Graves disease (*t* = 3.32, *p* = 0.021) and Hashimoto thyroiditis (*t* = 2.96, *p* = 0.012) in patients with vitiligo. Publication bias was not done in subclinical hyperthyroidism in vitiligo patients as there were insufficient observations.

![The three thyroid disorders in vitiligo patients with no publication bias **(A)** overt hyperthyroidism; **(B)** overt hypothyroidism; **(C)** subclinical hypothyroidism.](fendo-09-00803-g0003){#F3}

Discussion {#s4}
==========

Genome-wide association studies suggesting the relationship between vitiligo and thyroid disorders may be explained by the sharing of a subset of susceptibility gene ([@B89]--[@B97]). For example, genome-wide linkage analysis in families identified an autoimmunity susceptibility locus on chromosome 1 in patients with both vitiligo and Hashimoto\'s thyroiditis ([@B96]--[@B98]). In 2012, Vrijmanc et reported a systematic review about the prevalence of abnormal thyroid function test or elevated thyroid antibodies in vitiligo patients, covering 48 studies ([@B99]). The study reminds clinicians should be aware of the possibility of thyroid function changes in patients with vitiligo, however, it did not elaborate specific thyroid dysfunction in vitiligo patients. From a different point, the present systematic review summarized the results of the studies which have categorical diagnoses. The present review involving 77 studies with 3,643 vitiligo subjects supports a significant association between vitiligo and at least one thyroid disorders. The thyroid disorders were subclinical hyperthyroidism, overt hyperthyroidism, Graves disease, subclinical hypothyroidism, overt hypothyroidism, Hashimoto thyroiditis. Twenty-five studies reported the prevalence of subclinical hypothyroidism in vitiligo and the prevalence was the highest (6%) among the six thyroid disorders. Subclinical hyperthyroidism or Graves disease had the lowest prevalence (1%) in vitiligo patients, correspondingly, only approximately 10 studies were, respectively reported about these diseases.

A majority of investigators paid attention to overt hypothyroidism (54 studies) and overt hyperthyroidism (50 studies) in vitiligo patients, although the prevalence of these two disorders (3 and 2%) were lower than that of subclinical hypothyroidism. Overt hypothyroidism patients may experience weight gain, hair loss, dry skin, cold intolerance, constipation, muscle aches, or impaired memory ([@B100]--[@B102]). Overt hyperthyroidism patients may present with irritability, nervousness and heat intolerance ([@B101], [@B103]).

Our study investigated the potentially distorting factors, including area, gender, age, vitiligo type and stage of vitiligo. The prevalence of overt hyperthyroidism, overt hypothyroidism, Graves disease, and Hashimoto thyroiditis in Europe were higher than in Asia, in contrast, the prevalence of subclinical hypothyroidism in Europe were lower than in Asia. Genetic factor and iodine intaking habit may explain the disparity. The risk of thyroid dysfunction in female vitiligo patients is equal or greater than male, suggesting a gender-relationship between thyroid disorders and vitiligo. Men and women have sexual dimorphism of the immune response ([@B104], [@B105]). The British vitiligo guideline suggests that adult vitiligo patients should regularly screen for thyroid disorders. The present systematic review supports this recommendation in adult vitiligo patients with subclinical hyperthyroidism and overt hyperthyroidism. However, as for subclinical hypothyroidism, overt hypothyroidism and Hashimoto thyroiditis, children had higher prevalence than adult.

In the present review, all thyroid disorders were found in NSV, but not in SV. SV is characterized by early involvement of follicular melanocyte reservoir, early age of onset, and rapid stabilization ([@B106]), whereas NSV typically evolves over time and associates with thyroid disease frequently ([@B107]). Ethnic background may explain the disparity ([@B91], [@B107]). Different clinical subtypes of NSV have been described, including generalized, acrofacial, and vulgaris types. However, very few studies were included, so we can\'t draw a clear conclusion. As for the subgroup analysis between active vitiligo and stable vitiligo, 2 thyroid dysfunctions (overt hyperthyroidism and subclinical hypothyroidism) were studied but no definite results were found.

Several limitations of this meta-analysis must be considered. As there were insufficient studies, publication biases were not done about subclinical hyperthyroidism, and publication bias was found in Graves disease and Hashimoto thyroiditis. Studies about vitiligo type and stage were scant. This may have influenced confidence intervals and limited the generalizability of findings. Besides, 3 studies were not included due to the language restrictions.

In conclusion, the systematic review and meta-analysis showed that 6 thyroid disorders showed various prevalence in vitiligo. The highest prevalence was in subclinical hypothyroidism, and the lowest was in subclinical hyperthyroidism or Graves disease. The results of the current review provide useful estimates of the burden of thyroid disorders in vitiligo patients. Screening vitiligo patients for thyroid disorders seem reasonable, in an effort to detect potential thyroid diseases or to assess the risk of future onset.
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